Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

Tony Mok, Nelly Cherciu, Filiz Çay Şenler et al.|The Lancet|2019

Cited by 3.3k